FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Orthopedic Use of BPC 157 Sports Med Review Untitled The Peptide Landscape Is Shifting: What Secretary Kennedy's Joe Rogan Interview Could Mean for the Compounding Industry Frier Levitt FDA Peptide Regulation May Shift: What RFK Jr.'s Announcement Means for Compounding The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York